News

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Morgan

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, and Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present

Pfizer Inc. (NYSE: PFE) today introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core⁽¹⁾ compared to the third quarter of

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024.

Bernard Zovighian, chief executive officer

Several thousand green-shirted Humana employees will volunteer in Louisville on Aug. 21, marking the anniversary of the company’s founding, demonstrating Humana’s commitment to its hometown and

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

Humana Inc. (NYSE: HUM), a leading health and well-being company, launches a refreshed military-connected hiring strategy and earns recognition by U.S. Veterans Magazine as a Top Veteran-Friendly

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine

Agilent Technologies Inc., (NYSE: A) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column

Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study

In honor of National Pickleball Day, The Trust for the National Mall and Humana (NYSE: HUM) announce exciting program details for the three-day monumental event, National Mall of Pickleball

Agilent Technologies Inc., (NYSE: A) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and

Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2024 and raised its full-year 2024 guidance⁽¹⁾ for both Revenues and Adjusted⁽²⁾ diluted EPS.

The second-quarter 2024

Agilent Technologies Inc. (NYSE: A) today announced it has acquired Sigsense Technologies, a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights:

• 
  Revenue grew 15% year-over-year to

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX^® (fidanacogene elaparvovec), a gene therapy for the treatment

Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced a new multi-year agreement with Google Cloud to further modernize Humana’s cloud infrastructure and leverage

Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient